Rajesh C. Shrotriya, MD Chairman and Chief Executive Officer
In September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.
Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.
Dr. Shrotriya is a 2011 Ernst & Young Orange County Region Entrepreneur of the Year® award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Shrotriya was chosen from 15 finalists by a panel of independent judges.
Joseph Turgeon President and Chief Operating Officer
Mr. Turgeon has global responsibility for leading Commercial Operations, Medical and Clinical Development and Pharmaceutical Operations.
Prior to joining the Company, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President, Sales where he built and led the sales organization across multiple areas, including oncology, inflammation and bone health. Mr. Turgeon was responsible for launching most of the drugs and their dramatic growth at Amgen. He brings depth of experience in the oncology marketplace.
Mr. Turgeon holds a B.S. from Jacksonville University where he studied microbiology and economics.
Kurt Gustafson Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Mr. Gustafson has more than 20 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations.
Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as CFO of Amgen International and resided in Zug, Switzerland.
Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles.
Pramod K. Gupta, PhD Senior Vice President, Pharmaceutical Operations
Pramod Gupta is responsible for product development, and commercial manufacturing and supply chain, of Spectrum products. His product development responsibilities include chemical development, formulation development, analytical development, scale-up/manufacturing, stability studies, clinical supplies and intellectual property. His supply chain responsibilities include commercial product inventory management, product manufacturing and shipment, and contracts management.
Pramod has over 25 years’ experience in the pharmaceutical industry including Abbott, Baxter and Bausch & Lomb, where he held positions of increasing responsibilities. He has been part of over 12 approved NDAs and over 35 product launches globally. Pramod holds PhD in Pharmaceutical Sciences, has published more than 50 papers and 2 scientific books, and holds over 12 granted patents. He has also served as an expert committee member for the United States Pharmacopoeia.
Thomas J. Riga Senior Vice President and Chief Commercial Officer
Mr. Riga is responsible for the commercialization and sales of all Spectrum products in US and globally. Currently, Spectrum markets FUSILEV® (levoleucovorin) for Injection; FOLOTYN®; (pralatrexate injection); BELEODAQ™ (belinostat for injection) and ZEVALIN®;(ibritumomab tiuxetan) Injection for intravenous use and MARQIBO®; (vinCRIStine sulfate LIPOSOME injection).
Mr. Riga brings over 15 years of experience in the pharmaceutical and biotechnology industry. His experience spans sales, marketing, manufacturing, and corporate accounts. Throughout his career, Tom has delivered top tier results in a variety of functional areas within commercial.
Shiv Kapoor Vice President, Strategic Planning and Investor Relations
Avi N. Oler, CFA Vice President, Operations and Chief of Staff to the CEO
Bimal R. Shah Vice President, Corporate and Business Development
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.